Evidence map›Paper›PMID 42893848›Full record

ArticleFundamental & clinical pharmacology2026

Drug-Specific Associations of Angiotensin Receptor Blockers With Parkinson's Disease Risk in a Multicenter Electronic Health Record Cohort.

Kyle Tran, Jichen Yang, Sally Pham, Dylan Luong, Benjamin Andrew Martin, Stefanie Sasaki, Joshua Hahn, Richard Luu, Gha-Hyun Jeffrey Kim

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Fundamental & clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kyle TranDepartment of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California-Irvine, Irvine, California, USA.
Jichen YangDepartment of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California-Irvine, Irvine, California, USA.
Sally PhamDepartment of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California-Irvine, Irvine, California, USA.
Dylan LuongDepartment of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California-Irvine, Irvine, California, USA.
Benjamin Andrew MartinDepartment of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California-Irvine, Irvine, California, USA.ORCID https://orcid.org/0009-0001-1360-9435
Stefanie SasakiDepartment of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California-Irvine, Irvine, California, USA.
Joshua HahnDepartment of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California-Irvine, Irvine, California, USA.
Richard LuuDepartment of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California-Irvine, Irvine, California, USA.
Gha-Hyun Jeffrey KimDepartment of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California-Irvine, Irvine, California, USA.ORCID https://orcid.org/0000-0001-9073-2034

Funding

NIH HHS
6 · The paper itself

Abstract

backgroundAngiotensin receptor blockers (ARBs) have demonstrated neuroprotective effects in preclinical models of Parkinson's disease (PD), but individual ARBs differ in pharmacological properties that may influence their neuroprotective potential.

objectivesUsing large-scale hospital electronic health records of the University of California health system, we tested whether specific ARBs are associated with lower PD risk.

methodsWe conducted a new-user, active-comparator cohort study in the University of California Health Data Warehouse, encompassing 890 712 hypertensive patients across six academic medical centers from 2012 to 2025. Cox proportional hazards models estimated hazard ratios for individual ARB associations with incident PD, adjusting for demographics, nine preindex comorbidities, and index date. Robustness was assessed through propensity score matching and negative-control analysis.

resultsDrug-specific Cox analysis identified irbesartan (HR = 0.588, 95% CI 0.434 to 0.796, p = 0.0006) and olmesartan (HR = 0.797, 95% CI 0.665 to 0.956, p = 0.015) as associated with lower PD risk. Irbesartan survived Bonferroni correction for multiple comparisons, and propensity score matching supported both associations.

conclusionIn this large multicenter EHR cohort, irbesartan and olmesartan were associated with lower incident Parkinson's disease risk. These findings support further investigation of the renin-angiotensin system as a therapeutic target in Parkinson's disease and may inform the development or repurposing of agents with favorable central nervous system penetration and neuroprotective potential.

Indexed as

Angiotensin Receptor AntagonistsHypertensionIrbesartanNeuroprotective AgentsParkinson DiseaseAgedCohort StudiesElectronic Health RecordsFemaleHumansImidazolesMaleMiddle AgedPropensity ScoreProportional Hazards ModelsTetrazolesAngiotensin Receptor AntagonistsImidazolesIrbesartanNeuroprotective AgentsolmesartanTetrazolesangiotensin receptor blockersdrug repositioningirbesartanolmesartanParkinson's diseasepharmacoepidemiology

Identifiers

PMID42893848
PMCPMC13677279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.